Profile of infliximab in the treatment of pediatric Crohn’s disease
نویسندگان
چکیده
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.
منابع مشابه
Isolated cutaneous Crohn’s disease: A case report
This case report describes a patient with cutaneous signs in the genital and peri-anal region suspicious of Crohn’s disease without any intestinal symptom or sign. Inflammatory bowel disease can be associated with some cutaneous signs. However, in this paper, we report a patient with isolated cutaneous Crohn’s disease which is very rare (less than 100 case reports across the world). Our patient...
متن کاملGenital Involvement In Pre-Pubertal Pediatric Population: A Rare Aspect of Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease (IBD), characterized by chronic intestinal inflammation that causes the loss of immune tolerance leading to bizarre inflammatory signals and disruption of mucosal barriers. Environmental triggers and interaction of genetic determinants also play an indispensible role. In this case report, we present a pre-pubertal girl with intermittent and refra...
متن کاملINFLAMMATION AND INFLAMMATORY BOWEL DISEASE Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease
Background and aims: Treatment with infliximab induces remission in about 70% of patients with steroid refractory Crohn’s disease. Because Crohn’s disease is considered to be mediated by uncontrolled activation of mucosal T lymphocytes, we hypothesised that infliximab could induce apoptosis of T lymphocytes. Methods: Induction of apoptosis in vivo was studied in 10 patients with therapy refract...
متن کاملINFLAMMATORY BOWEL DISEASE Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease
Background and aims: To verify whether targeting defective mucosal T cell death underlies the sustained therapeutic benefit of infliximab in Crohn’s disease, we explored its in vivo proapoptotic effect after 10 weeks of treatment, and its in vitro killing activity on lamina propria T cells (LPT) and peripheral blood T cells (PBT), both isolated from Crohn’s disease patients. Methods: Endoscopic...
متن کاملIndividualized treatment with infliximab therapy in children with Crohn’s disease support shorter time intervals between infusions
OBJECTIVES To study the effect of an individualized treatment approach with regard to dosage intervals between infliximab infusions on the clinical outcome of pediatric Crohn's disease (CD). PATIENTS AND METHODS A retrospective analysis of medical records of all pediatric patients with CD who had been treated with infliximab between 1999 and 2007 in two Swedish counties, where an individualiz...
متن کامل